Serum predictive cytokine validation in Rheumatoid Arthritis to withdraw Orencia by using ultrasound analysis

Serum predictive cytokine validation in Rheumatoid Arthritis to withdraw Orencia by using ultrasound analysis - SOROBAN study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032316

Enrollment

Registered

2018-04-19

Start date

2016-12-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients aged >=18 years old at the time of informed consent 2)Patients who met the 2010 ACR/EULAR criteria 3)Previously untreated with JAK inhibitor or Biologics at the time of informed consent 4)Treatment naive early RA patients (duration<6 months) who do not achieve USIR during the first treatment of DMARDs for 3 months. 5)Patient who can fully understand the protocol and voluntarily consent in writing to participate in this study.(In the case of patients under 20 years old, we also obtain consent from parents)

Exclusion criteria

Exclusion criteria: 1) Current complication of malignant tumor 2) severe infection including active tuberculosis 3) ongoing or history of demyelinating disease 4) congestive heart disease 5) previous treatment with glucocorticoid, DMARDs and biologics

Design outcomes

Primary

Measure	Time frame
The remission rate of DAS, SDAI, CDAI, Boolean, mHAQ and USIR at Week 24	—

Countries

Japan

Contacts

Public ContactKenta Misaki

Kita-Harima Medical Center Rheumatology

kenta_misaki@kitahari-mc.jp0794-88-8800

Outcome results